CCL2-neutralising antibody

A CCL2-neutralizing antibody is a therapeutic monoclonal antibody designed to target and neutralize C-C motif chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1). CCL2 is a key chemokine that recruits monocytes, macrophages, and other immune cells to sites of inflammation and tumor microenvironments via its receptors, primarily CCR2. By blocking the interaction of CCL2 with its receptors, these antibodies aim to inhibit immune cell infiltration, reduce chronic inflammation, and disrupt tumor-promoting microenvironments. Clinical-stage candidates in this class have included carlumab (CNTO 888), which was investigated for various cancers, fibrosis, and inflammatory conditions, as well as preclinical candidates evaluated in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) to protect neuromuscular junctions from denervation.

Other names

anti-CCL2 antibodyanti-CCL-2 antibodyanti-CCL 2 antibodyanti-MCP-1 antibodyanti-MCP1 antibodyanti-MCP 1 antibodyCCL2-neutralizing antibodyCCL-2-neutralizing antibodyCCL 2-neutralizing antibodymonocyte chemoattractant protein-1 neutralizing antibody